Ezlopitant

Ezlopitant
Clinical data
Other namesCJ-11,974; (2S,3S)-2-Diphenylmethyl-3-[(5-isopropyl-2-methoxybenzyl)amino]quinuclidine[1]
Routes of
administration		By mouth
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
ExcretionUrine (32%), Feces (51%)
Identifiers
IUPAC name
  • (2S,3S)-2-Benzhydryl-N-[(5-isopropyl-2-methoxy-phenyl)methyl]quinuclidin-3-amine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC31H38N2O
Molar mass454.658 g·mol−1
3D model (JSmol)
SMILES
  • COc1ccc(cc1CN[C@H]2C3CCN(CC3)[C@H]2C(c4ccccc4)c5ccccc5)C(C)C
InChI
  • InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1
  • Key:XPNMCDYOYIKVGB-CONSDPRKSA-N

Ezlopitant (INN,[1] code name CJ-11,974) is an NK1 receptor antagonist.[2][3][4] It has antiemetic and antinociceptive effects.[5][6] Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued.[2]

See also

References

  1. 1 2 "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 44" (PDF). World Health Organization. pp. 194–5. Retrieved 17 November 2016.
  2. 1 2 Evangelista S (October 2001). "Eziopitant. Pfizer". Current Opinion in Investigational Drugs. 2 (10): 1441–3. PMID 11890362.
  3. ↑ Diemunsch P, Grélot L (September 2000). "Potential of substance P antagonists as antiemetics". Drugs. 60 (3): 533–46. doi:10.2165/00003495-200060030-00002. PMID 11030465. S2CID 25136161.
  4. ↑ Giardina GA, Gagliardi S, Martinelli M (August 2003). "Antagonists at the neurokinin receptors--recent patent literature". IDrugs: The Investigational Drugs Journal. 6 (8): 758–72. PMID 12917772.
  5. ↑ Tsuchiya M, Fujiwara Y, Kanai Y, et al. (November 2002). "Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret". Pharmacology. 66 (3): 144–52. doi:10.1159/000063796. PMID 12372904. S2CID 37936941.
  6. ↑ Tsuchiya M, Sakakibara A, Yamamoto M (January 2005). "A tachykinin NK1 receptor antagonist attenuates the 4 beta-phorbol-12-myristate-13-acetate-induced nociceptive behaviour in the rat". European Journal of Pharmacology. 507 (1–3): 29–34. doi:10.1016/j.ejphar.2004.11.028. PMID 15659291.


This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.